WS #16500
Eli Lilly reported a massive Q3 beat with $24.4B in revenue and raised full-year guidance, driven by Mounjaro sales exceeding $10B. Merck also topped estimates, buoyed by Keytruda and Gardasil. These results highlight the continued dominance of the GLP-1 weight-loss narrative and provide a safe-haven allocation for investors seeking growth that is insulated from the energy-driven inflationary environment. Visa reported a 13% sales rise in its fiscal fourth quarter, pointing to continued consumer spending power. Restaurant Brands also topped sales estimates as Burger King deals drive traffic. These data points suggest that while energy costs are rising, consumers are absorbing the inflation rather than pulling back, which supports the consumer discretionary sector despite the oil shock.
Healthcare and Pharma Strength
Eli Lilly reported a massive Q3 beat with $24.4B in revenue and raised full-year guidance, driven by Mounjaro sales exceeding $10B. Merck also topped estimates, buoyed by Keytruda and Gardasil. These results highlight the continued dominance of the GLP-1 weight-loss narrative and provide a safe-haven allocation for investors seeking growth that is insulated from the energy-driven inflationary environment.
Visa reported a 13% sales rise in its fiscal fourth quarter, pointing to continued consumer spending power. Restaurant Brands also topped sales estimates as Burger King deals drive traffic. These data points suggest that while energy costs are rising, consumers are absorbing the inflation rather than pulling back, which supports the consumer discretionary sector despite the oil shock.